Health Catalyst, Inc Common Stock (HCAT) is a publicly traded Healthcare sector company. As of May 21, 2026, HCAT trades at $1.29 with a market cap of $93.85M and a P/E ratio of -0.34. HCAT moved +2.36% today. Year to date, HCAT is -43.67%; over the trailing twelve months it is -67.26%. Its 52-week range spans $0.96 to $9.24. Analyst consensus is neutral with an average price target of $2.11. Rallies surfaces HCAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading HCAT stock inside the company?
Recent HCAT insider activity includes Landry Benjamin sold 27.43K, Larson-Green Julie sold 48.00K, Landry Benjamin sold 6.17K, and Landry Benjamin sold 6.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
HCAT Key Metrics
Key financial metrics for HCAT
Metric
Value
Price
$1.29
Market Cap
$93.85M
P/E Ratio
-0.34
EPS
$-3.74
Dividend Yield
0.00%
52-Week High
$9.24
52-Week Low
$0.96
Volume
0
Avg Volume
0
Revenue (TTM)
$302.48M
Net Income
$-265.26M
Gross Margin
0.00%
Recent HCAT Insider Trades
Landry Benjamin sold 27.43K (~$72.33K) on Dec 5, 2025.
Larson-Green Julie sold 48.00K (~$128.35K) on Dec 4, 2025.
Landry Benjamin sold 6.17K (~$20.70K) on Sep 5, 2025.
Landry Benjamin sold 6.06K (~$23.89K) on Jun 5, 2025.
Recent HCAT insider activity includes Landry Benjamin sold 27.43K, Larson-Green Julie sold 48.00K, Landry Benjamin sold 6.17K, and Landry Benjamin sold 6.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HCAT?
Yes. Rallies tracks HCAT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HCAT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HCAT. It does not provide personalized investment advice.
